Kyle Mikson CFA, an analyst from Canaccord Genuity, reiterated the Buy rating on Oxford Nanopore Technologies PLC. The associated price target remains the same with p180.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Kyle Mikson CFA has given his Buy rating due to a combination of factors that highlight Oxford Nanopore Technologies PLC’s strong market performance and growth potential. The company’s impressive first-half performance in 2025 was primarily driven by the robust adoption of its PromethION product range, which significantly boosted research revenue in regions like EMEA and APAC, despite a slight decline in AMR. This growth in research revenue, along with a strong performance in the Applied markets, particularly in Clinical and BioPharma sectors, underscores the company’s strategic execution and long-term growth prospects.
Moreover, Oxford Nanopore Technologies has reaffirmed its financial guidance for the near and medium term, projecting a consistent revenue increase and improved gross margins. The company’s differentiated product offerings and strategic initiatives to enhance gross margin, despite certain challenges, further solidify its competitive position in the market. Mikson believes that the current stock price does not fully reflect the company’s long-term growth potential, making it an attractive investment opportunity at this time.
In another report released today, Barclays also maintained a Buy rating on the stock with a £1.60 price target.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ONT in relation to earlier this year.